Viking Operating Income from 2010 to 2024

VKTX Stock

USD 51.99 0.60 1.14%

Viking Therapeutics Operating Income yearly trend continues to be fairly stable with very little volatility. Operating Income is likely to outpace its year average in 2024. Operating Income is earnings before interest and taxes (EBIT), representing the amount of profit Viking Therapeutics generates from its operations. View All Fundamentals

Operating Income

First Reported

2012-12-31

Previous Quarter

-34.1 M

Current Value

-36.6 M

Quarterly Volatility

9.9 M

Yuan Drop

Covid

Check Viking Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Viking Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 277.4 K, Interest Expense of 83.6 K or Selling General Administrative of 38.9 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 5.29. Viking financial statements analysis is a perfect complement when working with Viking Therapeutics Valuation or Volatility modules.

Check out the analysis of Viking Therapeutics Correlation against competitors.

For more information on how to buy Viking Stock please use our How to Invest in Viking Therapeutics guide.

Latest Viking Therapeutics' Operating Income Growth Pattern

Below is the plot of the Operating Income of Viking Therapeutics over the last few years. Operating Income is the amount of profit realized from Viking Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Viking Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Viking Therapeutics' Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Viking Therapeutics' overall financial position and show how it may be relating to other accounts over time.

Operating Income

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Operating Income

Timeline

Viking Operating Income Regression Statistics

	Arithmetic Mean	(32,863,059)
	Coefficient Of Variation	(102.92)
	Mean Deviation	26,799,514
	Median	(23,467,983)
	Standard Deviation	33,821,572
	Sample Variance	1143.9T
	Range	100.7M
	R-Value	(0.93)
	Mean Square Error	177.6T
	R-Squared	0.86
	Slope	(6,996,492)
	Total Sum of Squares	16014.6T

Viking Operating Income History

	2024	-95.8 M
	2023	-100.8 M
	2022	-70.4 M
	2021	-55.7 M
	2020	-42.7 M
	2019	-32.7 M
	2018	-26.2 M

Other Fundumenentals of Viking Therapeutics

Non Operating Income Net Other

Viking Therapeutics Operating Income component correlations

	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Common Stock	Total Assets	Total Current Assets	Short Term Debt	Net Tangible Assets	Current Deferred Revenue	Deferred Long Term Liab	Short Long Term Debt	Short Term Investments	Long Term Debt Total	Capital Surpluse	Treasury Stock	Net Invested Capital	Net Working Capital	Capital Stock
Total Stockholder Equity		-0.87	-0.82	0.67	0.31	0.88	1.0	1.0	-0.23	0.88	-0.83	-0.66	0.68	0.95	-0.61	0.9	-0.11	0.98	0.98	-0.61
Net Debt	-0.87		0.96	-0.87	-0.51	-0.79	-0.89	-0.88	0.15	-0.65	0.74	0.59	-0.62	-0.76	0.71	-0.84	0.1	-0.82	-0.82	0.71
Retained Earnings	-0.82	0.96		-0.92	-0.59	-0.78	-0.84	-0.84	0.03	-0.61	0.78	0.67	-0.69	-0.7	0.7	-0.83	0.0	-0.77	-0.77	0.7
Accounts Payable	0.67	-0.87	-0.92		0.72	0.64	0.7	0.7	-0.01	0.45	-0.63	-0.53	0.54	0.54	-0.66	0.69	-0.03	0.6	0.61	-0.66
Total Liab	0.31	-0.51	-0.59	0.72		0.44	0.36	0.35	0.05	0.25	-0.4	-0.34	0.39	0.31	-0.24	0.46	0.02	0.34	0.34	-0.24
Common Stock	0.88	-0.79	-0.78	0.64	0.44		0.88	0.88	-0.16	0.93	-0.91	-0.74	0.83	0.93	-0.24	0.99	0.07	0.92	0.93	-0.24
Total Assets	1.0	-0.89	-0.84	0.7	0.36	0.88		1.0	-0.22	0.88	-0.84	-0.66	0.69	0.94	-0.62	0.9	-0.11	0.97	0.97	-0.62
Total Current Assets	1.0	-0.88	-0.84	0.7	0.35	0.88	1.0		-0.22	0.88	-0.84	-0.66	0.69	0.94	-0.62	0.9	-0.11	0.97	0.97	-0.62
Short Term Debt	-0.23	0.15	0.03	-0.01	0.05	-0.16	-0.22	-0.22		-0.22	-0.16	-0.46	0.4	-0.29	0.01	-0.26	0.83	-0.28	-0.28	0.01
Net Tangible Assets	0.88	-0.65	-0.61	0.45	0.25	0.93	0.88	0.88	-0.22		-0.88	-0.7	0.75	0.94	-0.18	0.91	0.0	0.92	0.93	-0.18
Current Deferred Revenue	-0.83	0.74	0.78	-0.63	-0.4	-0.91	-0.84	-0.84	-0.16	-0.88		0.94	-0.94	-0.81	0.32	-0.88	-0.25	-0.82	-0.83	0.32
Deferred Long Term Liab	-0.66	0.59	0.67	-0.53	-0.34	-0.74	-0.66	-0.66	-0.46	-0.7	0.94		-0.95	-0.62	0.27	-0.68	-0.45	-0.64	-0.64	0.27
Short Long Term Debt	0.68	-0.62	-0.69	0.54	0.39	0.83	0.69	0.69	0.4	0.75	-0.94	-0.95		0.7	-0.19	0.77	0.52	0.7	0.7	-0.19
Short Term Investments	0.95	-0.76	-0.7	0.54	0.31	0.93	0.94	0.94	-0.29	0.94	-0.81	-0.62	0.7		-0.35	0.93	-0.11	0.99	0.99	-0.35
Long Term Debt Total	-0.61	0.71	0.7	-0.66	-0.24	-0.24	-0.62	-0.62	0.01	-0.18	0.32	0.27	-0.19	-0.35		-0.32	0.17	-0.45	-0.45	1.0
Capital Surpluse	0.9	-0.84	-0.83	0.69	0.46	0.99	0.9	0.9	-0.26	0.91	-0.88	-0.68	0.77	0.93	-0.32		-0.05	0.94	0.94	-0.32
Treasury Stock	-0.11	0.1	0.0	-0.03	0.02	0.07	-0.11	-0.11	0.83	0.0	-0.25	-0.45	0.52	-0.11	0.17	-0.05		-0.12	-0.12	0.17
Net Invested Capital	0.98	-0.82	-0.77	0.6	0.34	0.92	0.97	0.97	-0.28	0.92	-0.82	-0.64	0.7	0.99	-0.45	0.94	-0.12		1.0	-0.45
Net Working Capital	0.98	-0.82	-0.77	0.61	0.34	0.93	0.97	0.97	-0.28	0.93	-0.83	-0.64	0.7	0.99	-0.45	0.94	-0.12	1.0		-0.45
Capital Stock	-0.61	0.71	0.7	-0.66	-0.24	-0.24	-0.62	-0.62	0.01	-0.18	0.32	0.27	-0.19	-0.35	1.0	-0.32	0.17	-0.45	-0.45

Click cells to compare fundamentals

About Viking Therapeutics Financial Statements

Viking Therapeutics investors use historical fundamental indicators, such as Viking Therapeutics' Operating Income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Viking Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Operating Income	-100.8 M	-95.8 M
Non Operating Income Net Other	1.4 M	1.5 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Viking Stock Analysis

When running Viking Therapeutics' price analysis, check to measure Viking Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viking Therapeutics is operating at the current time. Most of Viking Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viking Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viking Therapeutics' price. Additionally, you may evaluate how the addition of Viking Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Viking Operating Income from 2010 to 2024

Latest Viking Therapeutics' Operating Income Growth Pattern

Viking Operating Income Regression Statistics

Viking Operating Income History

Other Fundumenentals of Viking Therapeutics

Viking Therapeutics Operating Income component correlations

About Viking Therapeutics Financial Statements

Also Currently Popular

Additional Tools for Viking Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY